Tempest Therapeutics (TPST) Interest & Investment Income (2012 - 2022)
Tempest Therapeutics (TPST) posted Interest & Investment Income of $213000.0 for Q3 2022, up 204.29% sequentially from $70000.0 in Q2 2022, and up 238.1% YoY from $63000.0 in Q3 2021.
Tempest Therapeutics (TPST) Interest & Investment Income (2012 - 2022) Analysis & Trends
Tempest Therapeutics has reported Interest & Investment Income for 10 years, with the latest figure at $213000.0 in Q3 2022.
- Quarterly Interest & Investment Income rose 238.1% year-over-year to $213000.0 in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $349000.0 (up 384.72% YoY) and the FY2017 annual result came in at $33000.0, down 94.99% from the prior year.
- Interest & Investment Income climbed to $213000.0 in Q3 2022 per TPST's latest filing, from $70000.0 in the prior quarter.
- Over five years, Interest & Investment Income peaked at $213000.0 in Q3 2022 and troughed at -$4000.0 in Q1 2018.
- A 4-year average of $35454.5 and a median of $5000.0 in 2018 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2018 and 2022: Interest & Investment Income sank 500.0% in 2018, then soared 2233.33% in 2022.
- Over 4 years, Interest & Investment Income stood at $5000.0 in 2018, then sank by 40.0% to $3000.0 in 2020, then surged by 2000.0% to $63000.0 in 2021, then soared by 238.1% to $213000.0 in 2022.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $213000.0, $70000.0, and $3000.0 for Q3 2022, Q2 2022, and Q1 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Tempest Therapeutics | 4.32 Mn | 3.52 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 213,000.00 |
| Jun 30, 2022 | 70,000.00 |
| Mar 31, 2022 | 3,000.00 |
| Sep 30, 2021 | 63,000.00 |
| Jun 30, 2021 | 3,000.00 |
| Mar 31, 2021 | 3,000.00 |
| Sep 30, 2020 | 3,000.00 |
| Jun 30, 2020 | 9,000.00 |
| Sep 30, 2018 | 5,000.00 |
| Jun 30, 2018 | 22,000.00 |
| Mar 31, 2018 | -4,000.00 |
| Dec 31, 2017 | -5,000.00 |
| Sep 30, 2017 | 27,000.00 |
| Jun 30, 2017 | 10,000.00 |
| Mar 31, 2017 | 1,000.00 |
| Dec 31, 2016 | 511,000.00 |
| Sep 30, 2016 | -31,000.00 |
| Jun 30, 2016 | 16,000.00 |
| Mar 31, 2016 | 163,000.00 |
| Dec 31, 2015 | -98,000.00 |